All In Biotech

Drug Trial Radar · NCT01876771

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

413

Actual

Start

Apr 29, 2014

Primary completion

Dec 2042

Study completion Dec 2042

Sponsor

Lead sponsor
AHS Cancer Control AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 13, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is approved in Canada, it is not publicly funded in Alberta. Lu-DOTA-TATE has been used at the Cross Cancer Institute to treat more than 300 patients with NETs since August, 2010. Our Lu-DOTA-TATE treatment was initially given under Health Canada's Special Access Programme (SAP), with each individual treatment requiring separate approval. In 2014, Health Canada requested we conduct a clinical trial with Lu-DOTA-TATE instead. The purpose of this study is to: 1) assess the efficacy of Lu-DOTA-TATE treatment in patients with somatostatin receptor positive tumours; 2) assess the safety of Lu-DOTA-TATE; 3) assess the effect of Lu-DOTA-TATE on Quality of Life and survival.

Conditions

  • Carcinoma, Neuroendocrine

Interventions

  • [177]Lu-DOTA-TATEDrug

    Peptide receptor radionuclide therapy (PPRT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Tumour response of the target lesion(s) through end of treatmentTime frame: At screening, 12-20 weeks after each treatment cycle, and 6 months and 1 year after the last treatment
  2. Median progression-free survivalTime frame: Up to 1 year after last treatment
  3. Lu-177 scan disease evaluationTime frame: Up to 3 days after each Lu-DOTA-TATE treatment
  4. Change in tumour marker levelsTime frame: At baseline, 12-20 weeks after each treatment cycle, and 6 months and 1 year after last treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.